REG - LungLife AI, INC - LungLife AI Laboratory achieves CAP accreditation

LungLife AIAnnouncement

19/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211119:nRSS8967Sa&default-theme=true

RNS Number : 8967S  LungLife AI, INC  19 November 2021

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

LungLife AI Clinical Laboratory achieves CAP accreditation

Independent inspection confirms highest standard of care for laboratory
patients

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer enhanced by artificial intelligence, announces that its clinical
laboratory in Thousand Oaks, California has been awarded accreditation by the
College of American Pathologists (CAP). The Company, whose clinical laboratory
is already CLIA certified, voluntarily sought the accreditation as part of its
on-going commitment to maintaining best in class quality systems.

 

The Company's laboratory processes have been independently assessed by the
CAP, the world's largest organisation of board-certified pathologists and
leading provider of laboratory accreditation and proficiency testing
programmes, during a recent on-site inspection designed to ensure the highest
standard of care for all laboratory patients.

 

As part of this process, the inspectors examine a laboratory's records and
quality control procedures, as well as laboratory staff qualifications,
equipment, facilities, safety programme and overall management. The U.S.
federal government recognises the CAP Laboratory Accreditation Program as
being equal-to or more-stringent than the government's own inspection
programme, and the Centers for Medicare and Medicaid Services (CMS) have
granted the CAP Laboratory Accreditation Program "deeming authority," which
allows for CAP accreditation in lieu of a CMS inspection.

 

Lara Baden, VP Clinical Operations, LungLife AI, commented: "We are proud of
the recognition of our quality by the College of American Pathologists through
receiving this accreditation, which reflects our commitment to maintaining the
highest standards of excellence in laboratory testing for patients and
ensuring that our work practices meet the rigorous CAP assessment standards.
This accreditation will provide ordering physicians and patients a further
degree of confidence in the results they are receiving for our LungLB® test
as well as for future products."

 

 

For further information please contact:

 

 LungLife AI, Inc.                                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                    Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)      Tel: +44 (0)20 7597 5970
 Daniel Adams / Virginia Bull / Cameron MacRitchie

 Walbrook PR Limited                                  Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                     (mailto:LungLifeAI@walbrookpr.com)
 Paul McManus / Alice Woodings                       Mob: 07980 541 893 / 07407 804 654

 

 

About LungLife

LungLife is a developer of clinical diagnostic solutions for lung cancer
enhanced by artificial intelligence. The Company's diagnostic solutions are
designed to make a significant impact in the early detection of lung cancer.

 

The Company's technology is a combination of the recovery of rare cells and
blood-based biomarkers shown to be altered in lung cancer. The Company employs
machine learning to improve biomarker detection, and intends to build a deep,
novel pool of lung cancer-related data for AI-enabled applications designed to
improve its diagnostic solutions over time.

 

The Company's core technologies are integrated in the LungLB® test, which is
intended to be used as a tool to provide physicians with additional
information to help in the decision-making process for people with
indeterminate lung nodules that may be lung cancer following a CT scan. There
are estimated to be over 1.5 million individuals with indeterminate lung
nodules diagnosed each year in the United States. The LungLB® test may have
additional utilities, the most significant of which is likely to be in
monitoring individuals for recurrence following surgical removal of cancerous
lung nodules.

 

The Company has completed a 149 subject pilot study to evaluate the LungLB®
test, which showed a well-balanced performance and a Positive Predictive Value
of 89 per cent. The Company is now gearing up to proceed to a larger,
multi-centre validation study to garner regulatory and reimbursement support
and facilitate commercialisation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAKVLFFFFLXFBD